Table 3.
The Results for the Relationship Between ATB Use and OS of Immune Checkpoint Inhibitors in NSCLC.
| N | Hazard ration (HR) | P for HR | Heterogeneity (P, I2) | Publication bias | |
|---|---|---|---|---|---|
| Overall survival | |||||
| Overall | 13 | 2.16 [1.79-2.60] | 0.000 | 0.028, 22.9% | Begg’s Test = 0.474 Egger’s test = 0.565 |
| Time of antibiotics use | |||||
| A group [−60, 0] | 6 | 2.55 [1.98-3.27] | 0.000 | 0.365, 8.0% | Begg’s Test = 1.000 Egger’s test = 0.684 |
| B group [−30, 0 ] | 3 | 2.93 [2.13-4.04] | 0.0000 | 0.445, 0.0% | Begg’s Test = 0.296 Egger’s test = 0.457 |
| C group [−60,30] | 5 | 1.72 [1.30-2.28] | 0.000 | 0.016, 67.2% | Begg’s Test = 0308 Egger’s test = 0.398 |
| D group [−30,30] | 3 | 1.35 [0.92-1.99] | 0.124 | 0.011, 77.7% | Begg’s Test = 1.000 Egger’s test =/ |
| E group [0, 30 ] | 3 | 1.59 [1.07-2.39] | 0.023 | 0.023, 73.59% | Begg’s Test = 1.000 Egger’s test =/ |
| F group [During] | 6 | 1.74 [1.43-2.44] | 0.000 | 0.005, 69.9% | Begg’s Test = 1.000 Egger’s test = 0.600 |
| ICI drug | |||||
| PD-1 inhibitor | 4 | 2.50 [1.71-3.64] | 0.000 | 0.756, 0.0% | Begg’s Test = 0.308 Egger’s test = 0.050 |
| PD-1/PD-L1/CTLA-4 inhibitor | 9 | 2.06 [1.66-2.55] | 0.000 | 0.007, 62% | Begg’s Test = 1.000 Egger’s test = 0.955 |
| Sample size | |||||
| <100 | 5 | 2.76 [1.80-4.03] | 0.000 | 0.575, 0.0% | Begg’s Test = 0.462 Egger’s test = 0.222 |
| ≥100 | 8 | 2.00 [1.61-2.47] | 0000 | 0.012, 61% | Begg’s Test = 0.462 Egger’s test = 0.472 |
| Country | |||||
| Asia | 3 | 2.72 [1.77-4.18] | 0.000 | 0.481, 0.0% | Begg’s Test = 0.296 Egger’s test = 0.146 |
| No-Asia | 8 | 2.05 [1.66-2.52] | 0.000 | 0.017, 5.4% | Begg’s Test = 1.000 Egger’s test = 0.891 |